Tagrisso

Active Ingredient(s): Osimertinib
FDA Approved: * November 13, 2015
Pharm Company: * ASTRAZENECA PHARMS
Category: Cancer

Osimertinib, sold under the brand name Tagrisso,[3] is a medication used to treat non-small-cell lung carcinomas with specific mutations.[4][5] It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor. The most common side effects include diarrhea, rash, musculoskeletal pain, dry skin, skin inflammation around nails, sore mouth, fatigue and cough.[6] Osimertinib was approved for medical use in the Unit... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Tagrisso 40 1/1 Oral Tablet, Film Coated
NDC: 0310-1349
Labeler:
Astrazeneca Pharmaceuticals Lp
Tagrisso 80 1/1 Oral Tablet, Film Coated
NDC: 0310-1350
Labeler:
Astrazeneca Pharmaceuticals Lp